The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://charliegszv313032.wikibriefing.com/3953980/glp_3_retatrutide_a_comparative_analysis